



ACERUS TO REPORT 2017 FINANCIAL RESULTS AND HOST INVESTOR CALL

Toronto, Canada, March 14, 2018 – Acerus Pharmaceuticals Corporation (TSX:ASP) will announce financial results for the three and twelve month periods ending December 31, 2017 on Wednesday, March 21, 2018 before market opens. The company will host a conference call on Wednesday, March 21, 2018 at 8:30 a.m. Eastern Time.

To access the call live, please dial 416-340-2216 or 1-866-225-2055. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 11:59 p.m. Eastern Time on Wednesday, March 28, 2018 by dialing 905-694-9451 or 1-800-408-3053, using access code: 3999287#.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men's and women's health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

Acerus currently has three marketed products: Estrace®, a product for the symptomatic relief of menopausal symptoms, is commercialized in Canada; Natesto®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism, is commercialized in Canada and the U.S; and UriVarx®, a Natural Health Product that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. UriVarx® was recently approved by Health Canada and will be offered over-the-counter to Canadians dealing with such symptoms. In addition, Natesto® has been licensed for distribution in 29 additional countries worldwide. Marketing approvals in jurisdictions outside of North America are expected to take place over the course of the coming years. Acerus' pipeline includes four innovative products: Elegant™ Vaginal Moisturizer, which provides comfort to women suffering from vaginal dryness, and Elegant™ pH, which is a pH balanced vaginal product; Gynoflor™, an ultra-low dose vaginal estrogen combined with a probiotic, for which a NDS has been filed in Canada for the treatment of vaginal atrophy, restoration of vaginal flora and treatment of certain vaginal infections; and Tefina™, a clinical stage product aimed at addressing a significant unmet need for women with female sexual dysfunction. Finally, Acerus owns or has a license to numerous patents relating to proprietary delivery systems as well as novel formulations of products currently in the early stage of development.

Acerus' shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow us on [Twitter](#) and [LinkedIn](#).

#

Contact

Luc Mainville
Interim CEO
Acerus Pharmaceuticals Corporation
lmainville@aceruspharma.com
(905) 817-8194